Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.（ADVM）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ADVM · 截至 2025年9月30日
股东结构概览
50
机构持有人数
▼ 7 vs Q2
$61.46M
机构持仓总市值
▲ $32.42M vs Q2
22.08M
总流通股
freeFloat 62.34%
13.57M
13F 申报持股数
▲ 63,488 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ADVM 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BML CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.06M | 14.55% | 14.55% | $13.85B | Nov 10, 2025 | — held |
PRINCIPIA WEALTH ADVISORY, LLC biological products, (no diagnostic substances) | 2.08M | 9.89% | 9.89% | $9.41B | Feb 10, 2026 | ▲ 48.8K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 2.08M | 9.89% | 9.89% | $9.41B | Nov 14, 2025 | ▲ 1.01M |
TCG CROSSOVER MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.67M | 7.94% | 7.94% | $7.56B | Nov 17, 2025 | ▼ 128.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 872.0K | 4.15% | 4.15% | $3.95B | Nov 7, 2025 | ▼ 11.9K |
5AM VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 541.7K | 2.58% | 2.58% | $2.45B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 402.6K | 1.92% | 1.92% | $1.82B | Nov 14, 2025 | ▼ 94.7K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 363.5K | 1.73% | 1.73% | $1.65B | Nov 13, 2025 | ▼ 207.2K |
PALE FIRE CAPITAL SE biological products, (no diagnostic substances) | 363.3K | 1.73% | 1.73% | $1.65B | Nov 13, 2025 | ▲ 4.6K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 324.4K | 1.54% | 1.54% | $1.47B | Nov 14, 2025 | ▼ 17.9K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
10
增持
+1.19M 股5
新建仓
首次建仓22
减持
−864.7K 股0
清仓
完全退出净股数变化（前50家）
+329.6K
+1.19M / −864.7K
净新增持仓人
-7
新建 5 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ADVM 内幕交易记录
数据来源：SEC Form 4
10
买入笔数
102
卖出笔数
0.10
买卖比
$9M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | Award | 500,000 | — | — | 522.7K | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 25,000 | $3.56 | $89.0K | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 200,000 | $7.15 | $1.43M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 93,000 | $7.50 | $697.5K | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 351,513 | $3.56 | $1.25M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 522,666 | $3.56 | $1.86M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 110,420 | $10.14 | $1.12M | 0 | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | Award | 150,000 | — | — | 157.3K | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | D-Return | 39,476 | $10.14 | $400.3K | 0 | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | D-Return | 78,750 | $4.20 | $330.8K | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Adverum Biotechnologies, Inc.（ADVM）主要由机构投资者持有，机构持股比例约为 61.5%。公司内部人员持股约 37.66%，散户及公众持股约占剩余的 0.89%。
Adverum Biotechnologies, Inc. 最大机构股东为 BML CAPITAL MANAGEMENT, LLC，截至 September 30, 2025 持有约 3.06 million 股，占总流通股的 14.55%。
目前共有 50 家机构持有 ADVM 股票，合计持仓市值约 $61,458,813，数据来源为最新 SEC 13F 申报。
常见问题
ADVM ownershipAdverum Biotechnologies, Inc.（ADVM）主要由机构投资者持有，机构持股约 61.5%。最大股东为 BML CAPITAL MANAGEMENT, LLC，持股比例 14.55%。内部人员持股约 37.66%。数据来源 SEC Form 13F，截至 September 30, 2025。